Azacitidine (NCT05401097)

Name: Azacitidine trial for Acute Myeloid Leukemia (NCT05401097)
Uploaded: 2026-10-31T22:57:41.354Z
Duration: 1 min 17 s
Description: Azacitidine trial for Acute Myeloid Leukemia (NCT05401097). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05401097.

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study): a one-minute explainerNCT054010971 min

Azacitidine trial for Acute Myeloid Leukemia (NCT05401097). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with newly diagnosed IDH1- or IDH2-mutated acute myeloid leukemia who cannot receive, or decline, intensive induction chemotherapy.

The idea: random assignment tests two treatment orders. One starts azacitidine with ivosidenib for IDH1 or enasidenib for IDH2, then uses azacitidine with venetoclax after failure; the other reverses this order. IDH inhibitors target the altered enzyme; venetoclax blocks the BCL2 survival protein. Marrow biopsies assess response and resistance.

This phase 2 study plans 125 patients. Alice Mims leads at Ohio State, Columbus; four US sites recruit.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.